Saturday 17 October 2026
Export ASBP’s income statement to Excel — free account
Aspire-Lakewood Holdings, Inc.
ASBP Healthcare Biotechnology
Aspire-Lakewood Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,200.00. In the quarter to June 2026, EPS grew 97.5%, free cash flow fell 85.5% and total debt fell 79.7%, each against the same quarter a year earlier.
8.78
0.14
+1.62%
Follow ASBP
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 397.60 | 402.80 | 435.20 | 2.84 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 424.00 | 472.00 | 578.80 | 632.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 0 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | (1.61) | |||||
| EBT | — | — | — | — | — | 0 | 3 | 4 | (1) | (24) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (394,853.23) | |||||
| Net income | — | — | — | — | — | 0 | 3 | 4 | (1) | (24) | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | 8 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | ||||
| Earnings | — | — | — | — | — | (4.90) | 558.23 | 1,973.26 | (57.02) | (491.89) | |||||
| Cash flow | — | — | — | — | — | (45.88) | (234.80) | (283.96) | (11.53) | (98.87) | |||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | (45.88) | (234.80) | (283.96) | (11.53) | (98.87) | |||||
| Book value | — | — | — | — | — | (0.10) | (1,656.32) | (140.04) | (66.96) | (128.04) | |||||
| Shares, m | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (0.42) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 0 | (1) | (1) | 0 | (5) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | 0 | (1) | (1) | 0 | (5) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | 1 | 0 | (2) | (6) | ||||
| Total debt | — | — | — | — | — | 0 | — | — | 14 | 3 | |||||
| Net debt | — | — | — | — | — | 0 | 0 | — | 14 | 2 | |||||
| Shareholders’ equity | — | — | — | — | — | 0 | (10) | 0 | (2) | (6) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | 2.22 | 2.79 | (13.01) | (3,353.09) | ||||
| ROIC | — | — | — | — | — | (6.69) | 0.00 | 0.00 | (6.19) | 0.00 | |||||
| ROE | — | — | — | — | — | 0.00 | (67.22) | (87.02) | 140.68 | 618.49 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Aspire-Lakewood Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CTXR Citius Pharmaceuticals, Inc. | $12.6M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| CASIF CASI Pharmaceuticals Inc. | $12.4M | — (loss-making) | — (loss-making) | −45.93% (below 0%: shrinking) | n/m | −23,251.69% (below 0%: shrinking) | 51.14% | (147.67%) | Compare |
| AEON AEON Biopharma, Inc. | $12.1M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | Compare |
| ASBP Aspire-Lakewood Holdings, Inc. | $12.1M | 0.2× | — | — | n/m | −85.54% (below 0%: shrinking) | (47.70%) | (4,244.37%) | |
| ACTU Actuate Therapeutics, Inc. | $12.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| PLUR Pluri Inc. | $11.9M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| INAB IN8bio, Inc. | $11.7M | — (loss-making) | — | — | n/m | −1.30% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ENSC Ensysce Biosciences, Inc. | $11.6M | — (loss-making) | — (loss-making) | −15.10% (below 0%: shrinking) | n/m | +27.50% (above 0%: growing) | 100.00% | (221.28%) | Compare |
| PASG Passage Bio, Inc. | $11.6M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $11.9M | — | — | −15.83% | — | −32.67% | 54.82% | (73.83%) |
Aspire-Lakewood Holdings, Inc. (ASBP) key facts
- Aspire-Lakewood Holdings, Inc. (ASBP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Aspire-Lakewood Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,200.00.
- As of October 16, 2026, ASBP traded at $8.78, a market capitalization of $12.1 million.
- Return on equity was 618.5% and debt-to-equity 0.00.
- Its Altman Z-score is −83.47 (distress zone) for fiscal 2025.